id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5966-0013,FDA,FDA-2017-D-5966,Breakthrough Devices Program; Guidance for Industry and Food and Drug Administration Staff Document,Other,Guidance,2018-12-19T05:00:00Z,2018,12,2018-12-19T05:00:00Z,,2023-09-15T15:37:50Z,,0,0,09000064839b2ddb
FDA-2017-D-5966-0012,FDA,FDA-2017-D-5966,"Breakthrough Devices Program; Guidance for Industry and Food and
Drug Administration Staff; Availability",Notice,Notice of Availability,2018-12-19T05:00:00Z,2018,12,2018-12-19T05:00:00Z,,2024-11-12T22:53:05Z,2018-27433,1,0,09000064839b2697